about
New, improved treatments for Chagas disease: from the R&D pipeline to the patientsActions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on Trypanosoma cruziDevelopment of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas DiseaseComparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' diseaseCurrent and developing therapeutic agents in the treatment of Chagas diseaseIn vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi.Aryloxyethyl Thiocyanates Are Potent Growth Inhibitors of Trypanosoma cruzi and Toxoplasma gondii.Clinical aspects of Chagas disease and implications for novel therapies.Opportunities and challenges in chronic Chagas cardiomyopathyAromatic diamidines as antiparasitic agents.Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthaseAn update on the management of Chagas cardiomyopathy.Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agentsReversible cysteine protease inhibitors show promise for a Chagas disease cure.Congenital transmission of Chagas disease: a clinical approach.Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence.Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).Targeting CYP51 for drug design by the contributions of molecular modeling.Antitrypanosomal properties of Panax ginseng C. A. Meyer: new possibilities for a remarkable traditional drug.Identification in silico and in vitro of novel trypanosomicidal drug-like compounds.Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease.Anti-trypanosomatid activity of ceragenins.Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.Effects of (1E,4E)-2-Methyl-1,5-bis(4-nitrophenyl)penta-1,4-dien-3-one on Trypanosoma cruzi and Its Combinational Effect with Benznidazole, Ketoconazole, or Fluconazole.Crystallization and preliminary X-ray analysis of aspartate transcarbamoylase from the parasitic protist Trypanosoma cruzi.A preliminary crystallographic analysis of the putative mevalonate diphosphate decarboxylase from Trypanosoma brucei.Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivativesIn vitro activity of thienyl-2-nitropropene compounds against Trypanosoma cruzi.Ergosterol biosynthesis and drug development for Chagas disease.Chagas disease: a proposal for testing policy for solid-organ transplant in the United States.Use of clomipramine as chemotherapy of the chronic phase of Chagas disease.A solanesyl-diphosphate synthase localizes in glycosomes of Trypanosoma cruzi.Liver transplantation from deceased donors serologically positive for Chagas disease.Cysteine protease inhibitors as potential antiparasitic agentsSynthesis and Biological Activity of Sterol 14α-Demethylase and Sterol C24-Methyltransferase InhibitorsEffects of Inhibitors of [Delta]24(25)-Sterol Methyl Transferase on the Ultrastructure of Epimastigotes of Trypanosoma cruzi
P2860
Q21092295-49D91EB4-6693-446B-B7E3-539E1269C42FQ28474880-7DFE4073-1E01-4B97-BE6F-96558FD4A6ADQ28548320-0345DCEC-222D-4198-8E89-C0D3AD212F1FQ33722151-9F1EB2C7-CD6A-46E6-B732-F5F37B7F1CFCQ34170132-EA442B2D-DAD5-41AF-A020-FAA0874583CEQ35125554-02364604-D3BC-4E1D-A1E2-0BE23E35E297Q35660950-C72EA69A-C8E3-4479-B837-A0B808EEBA81Q35676177-0706526D-BBC8-42A3-A0C2-105C9A5AC539Q36108560-2626A674-2CE6-4481-9F6F-507A155B750CQ36210897-DD2E6507-DEF9-4A0A-9DB7-232F596E43AAQ36580508-78EB9A94-06F0-40D4-A204-615A8679D554Q36901974-320B2587-6F68-485F-AA23-D8EB00B01397Q37318751-5828FE3C-D4FB-4330-9BBE-AD579A3B0A43Q37544765-C7D12667-FE61-4D53-B767-E67FD427667BQ37778830-B18167A0-8FFC-4307-9F96-20215BE51F88Q37998091-87669C15-5226-4C63-BAA5-67E16A26E1B8Q38017721-5F36931C-2ED6-48CA-B5C1-E168A731CC80Q38845466-2A306D6C-9DF5-418E-8718-A8A97FE5C8B5Q38917135-BFC4E7D8-139E-4D4F-A3A0-0EA00C03CFC7Q39369782-1CD727FA-C285-4B95-8EC2-33EE83BD181CQ39382508-72D5D742-3FD3-4A27-9F02-D3E5FCD98BB6Q39755589-657A9DF0-1142-4300-B146-B578C693EC1BQ39767506-6217C990-500C-4B93-921B-90280A821804Q40290159-62D5E70D-2E0E-4A35-96F7-0025C1E873BEQ40394480-3623D014-06E3-48DA-B340-7AABCB453994Q41948216-1A55C420-2A01-4B24-BBF9-10B66396916AQ42000804-C0BBDA4C-CF01-4A3E-9B61-F42665E06960Q42101450-91E0E272-0903-4004-A743-37C5FFD5CB55Q42112211-3A158405-F1DC-484A-A86A-80CC4B379A7FQ43212004-8D3648C9-C6F3-4B83-98C6-94E3C34BD5AEQ43276756-24CA5657-2B54-4009-9122-167E5A41D79CQ45753286-2E2B81C6-E668-4E4B-B087-CEA5BF94C2C4Q46005772-FB909BB7-323F-4978-87F6-0BE794D9E93BQ48083904-02B37699-788E-4689-83FD-1769F8A0808FQ48418278-35FE29E9-F9A9-4781-B661-4FA3693289D0Q58423121-726F4657-6E2C-4669-842A-AE7FB48DD501Q58842234-BB5EE280-EAAF-4FCC-B41A-C27122920291Q58851531-B1B271AD-909E-49BA-A275-FA7CB4EFE29D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemotherapy of Chagas disease.
@ast
Chemotherapy of Chagas disease.
@en
Chemotherapy of Chagas disease.
@nl
type
label
Chemotherapy of Chagas disease.
@ast
Chemotherapy of Chagas disease.
@en
Chemotherapy of Chagas disease.
@nl
prefLabel
Chemotherapy of Chagas disease.
@ast
Chemotherapy of Chagas disease.
@en
Chemotherapy of Chagas disease.
@nl
P356
P1476
Chemotherapy of Chagas disease.
@en
P2093
Julio A Urbina
P304
P356
10.2174/1381612023396177
P577
2002-01-01T00:00:00Z